Already down nearly 38% in twelve months, Implanet stock declines 8.5%
The Bordeaux-based spinal surgery implant manufacturer retreats sharply during trading, following the publication of revenue growth over nine months. The stock pulls back after gaining ground over the past week.
Sales of €10.57 million driven by the United States, which has become the leading market
Implanet declines 8.6% to €0.17 during trading, while the overall Paris market is oriented upward (the CAC 40 gains 0.54%). The decline follows the publication on October 13 after closing of revenue of €10.57 million for the first nine months of 2026, compared to €8.73 million a year earlier, representing an increase of 21%. In the third quarter, the United States became the group's leading market, with sales up 32% to €1.40 million.
Quarterly growth stands at 18%, after 27% in the second quarter, and the distribution of medical equipment (+46%) is growing faster than spinal implants (+6%). The group also indicates that its cash position is €0.82 million, a level that leads it to examine its financing options, and that its funding needs linked to growth are anticipated. It also cites, among its prospects, a technological partnership with Sanyou Medical, which should enable the launch of new products from 2027 onwards.
A rebound of nearly 8% over the week, RSI at 68 before today's decline
With this decline, the stock returns near its 50-day moving average, located at €0.17, after gaining 7.7% over seven days. The price remains 6.25% above the MA20 (€0.16) and 15% below the MA200 (€0.20). The RSI at 68 reflects the strength of the recent recovery, which is taking place in a context of a 37.9% decline over one year. On the levels side, support at €0.16 and resistance at €0.19 now frame today's price action.
